DiscoverEAU PodcastsESMO 2025 special: Prof. Vulsteke presents KEYNOTE-905/EV303 study results
ESMO 2025 special: Prof. Vulsteke presents KEYNOTE-905/EV303 study results

ESMO 2025 special: Prof. Vulsteke presents KEYNOTE-905/EV303 study results

Update: 2025-10-22
Share

Description

UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Christof Vulsteke (BE) on the design and results of the phase III KEYNOTE 905/EV303 study: Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. 

This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

ESMO 2025 special: Prof. Vulsteke presents KEYNOTE-905/EV303 study results

ESMO 2025 special: Prof. Vulsteke presents KEYNOTE-905/EV303 study results

European Association of Urology